International (Zava and other markets)
Rest of World revenue reached $131.4 million in Q2 2026, up from $7.5 million a year earlier, helped by the Eucalyptus deal closing in June.
The numbers
What it is
The company's business outside the US. It started with the Zava acquisition, which added UK and European operations in Germany, France, Ireland and Spain, and it grew further when Eucalyptus closed in June 2026.
Why it matters to the stock. International is now the fastest-growing part of reported revenue. Its margins and regulatory rules differ from the US, so the mix matters for how the group's margin is read.
News
Hims & Hers names chief medical officers for the UK and Australia
Hims & Hers named Kultar Garcha, MD, as Chief Medical Officer for the UK and EMEA, and Matt Vickers as Chief Medical Officer of Hims Australia.
Hims & Hers Q2 2026 revenue up 38% to $753 million, but net loss and margin squeeze
Hims & Hers reported second-quarter 2026 revenue of $753.2 million, up 38%, with 2.891 million subscribers.
Hims & Hers completes Eucalyptus acquisition, adding Australia and more customers
Hims & Hers closed its acquisition of Eucalyptus under the terms of the February agreement.
Hims & Hers agrees to buy Eucalyptus in a deal worth up to $1.15 billion
Hims & Hers signed a definitive agreement to acquire Eucalyptus, an Australian-founded digital health company, for up to $1.15 billion.